These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21554162)

  • 1. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
    Boumber Y; Younes A; Garcia-Manero G
    Expert Opin Investig Drugs; 2011 Jun; 20(6):823-9. PubMed ID: 21554162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.
    Le Tourneau C; Siu LL
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1247-54. PubMed ID: 18616420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
    Bonfils C; Kalita A; Dubay M; Siu LL; Carducci MA; Reid G; Martell RE; Besterman JM; Li Z
    Clin Cancer Res; 2008 Jun; 14(11):3441-9. PubMed ID: 18519775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
    Siu LL; Pili R; Duran I; Messersmith WA; Chen EX; Sullivan R; MacLean M; King S; Brown S; Reid GK; Li Z; Kalita AM; Laille EJ; Besterman JM; Martell RE; Carducci MA
    J Clin Oncol; 2008 Apr; 26(12):1940-7. PubMed ID: 18421048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
    Buglio D; Mamidipudi V; Khaskhely NM; Brady H; Heise C; Besterman J; Martell RE; MacBeth K; Younes A
    Br J Haematol; 2010 Nov; 151(4):387-96. PubMed ID: 20880107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.
    Cai J; Zhang Q; Lin K; Hu L; Zheng Y
    Biomed Res Int; 2015; 2015():517295. PubMed ID: 26357656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.
    Zhang Q; Wu H; Wen C; Sun F; Yang X; Hu L
    Int J Clin Exp Pathol; 2015; 8(8):9320-5. PubMed ID: 26464683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entinostat for treatment of solid tumors and hematologic malignancies.
    Knipstein J; Gore L
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.
    El-Khoury V; Moussay E; Janji B; Palissot V; Aouali N; Brons NH; Van Moer K; Pierson S; Van Dyck E; Berchem G
    Mol Cancer Ther; 2010 May; 9(5):1349-60. PubMed ID: 20406947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
    Ma J; Zhang Q; Wang X
    Xenobiotica; 2014 Sep; 44(9):849-54. PubMed ID: 24588344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
    Garcia-Manero G; Assouline S; Cortes J; Estrov Z; Kantarjian H; Yang H; Newsome WM; Miller WH; Rousseau C; Kalita A; Bonfils C; Dubay M; Patterson TA; Li Z; Besterman JM; Reid G; Laille E; Martell RE; Minden M
    Blood; 2008 Aug; 112(4):981-9. PubMed ID: 18495956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.
    El-Khoury V; Pierson S; Szwarcbart E; Brons NH; Roland O; Cherrier-De Wilde S; Plawny L; Van Dyck E; Berchem G
    Leukemia; 2014 Aug; 28(8):1636-46. PubMed ID: 24418989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
    Chia K; Beamish H; Jafferi K; Gabrielli B
    Mol Pharmacol; 2010 Sep; 78(3):436-43. PubMed ID: 20538840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histone acetylation modification with MGCD0103, a histone deacetylase inhibitor, on nuclear reprogramming and the developmental competence of porcine somatic cell nuclear transfer embryos.
    Jin L; Zhu HY; Guo Q; Li XC; Zhang YC; Cui CD; Li WX; Cui ZY; Yin XJ; Kang JD
    Theriogenology; 2017 Jan; 87():298-305. PubMed ID: 27742403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
    Sung V; Richard N; Brady H; Maier A; Kelter G; Heise C
    Cancer Sci; 2011 Jun; 102(6):1201-7. PubMed ID: 21375679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
    Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S; Li X; Zang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.
    Zhou N; Moradei O; Raeppel S; Leit S; Frechette S; Gaudette F; Paquin I; Bernstein N; Bouchain G; Vaisburg A; Jin Z; Gillespie J; Wang J; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Lu A; Rahil J; MacLeod AR; Li Z; Besterman JM; Delorme D
    J Med Chem; 2008 Jul; 51(14):4072-5. PubMed ID: 18570366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.